Torrent Pharma Stock Up by More Than 4% After June Quarter Result

Mumbai, July 29, 2025 – Shares of Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM) hit a new 52-week high of ₹3,784 today. This, after the company’s net profit in the June quarter increased year-on-year by 20%.

At 3:20 p.m. the stock is up by 4.04% at Rs 3,769.

Stock Performance Snapshot

As of 1:33 PM IST, Torrent Pharmaceuticals shares have gained 3.56% trading at ₹3,752 on July 29, 2025. Torrent Pharmaceuticals shares have gained 17% over the last year, 9.7% year-to-date, and 10.09% in the previous month.

Torrent Pharmaceuticals Ltd. opened trading at ₹3,660.20 and touched an intraday high of ₹3,784.80, marking its 52-week high. Over the past year, it has ranged between a low of ₹2,886.45 and its current peak of ₹3,784.80.

Torrent Pharma Q1FY26 Earnings

• Revenue from Operations stood at ₹3,178 crore in Q1 FY26, reflecting an 11% year-on-year (YoY) growth from ₹2,859 crore in Q1 FY25 and a 7% quarter-on-quarter (QoQ) rise from ₹2,959 crore in Q4 FY25.
• Operating EBITDA increased to ₹1,032 crore in Q1 FY26 (including exceptional income), up 14% YoY and 14% QoQ compared to ₹904 crore in both Q1 FY25 and Q4 FY25.
• EBITDA Margin improved to 32.5% in Q1 FY26, compared to 31.6% in Q1 FY25 and 30.6% in Q4 FY25.
• Net Profit rose to ₹548 crore in Q1 FY26, marking a 20% YoY increase from ₹457 crore and a 10% QoQ growth from ₹498 crore.
• Net Profit Margin expanded to 17.2% in Q1 FY26, up from 16.0% in Q1 FY25 and 16.8% in Q4 FY25.
• R&D Spend reached ₹157 crore in Q1 FY26, reflecting a 16% YoY rise from ₹135 crore and a 3% QoQ increase from ₹153 crore.

About Torrent Pharma

Torrent Pharmaceuticals Ltd is a prominent Indian pharmaceutical company involved in the research, development, manufacturing, and marketing of generic drug formulations.

It serves as the flagship entity of the Torrent Group, which also operates in sectors like power and city gas distribution. It is a listed pharma major with operations in over 50 countries. The company operates 8 manufacturing units and employs over 750 scientists across its R&D operations.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations